Picture of Pixium Vision SA logo

ALPIX Pixium Vision SA Share Price

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+72.5%
3m+137.64%
6m-86.65%
1yr-89.44%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-96.06%
50d MA+40.62%
200d MA-79.37%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-637%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Pixium Vision SA EPS forecast chart

Profile Summary

Pixium Vision SA is a France-based company that specializes in sensory neuromodulation. The Company is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The Company develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The Company has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
December 14th, 2011
Public Since
June 19th, 2014
No. of Employees
42
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
fr flag iconEuronext - Paris
Shares in Issue
1,385,739.34

ALPIX Share Price Performance

Upcoming Events for ALPIX

Q1 2024 Pixium Vision SA Earnings Release

Pixium Vision SA Annual Shareholders Meeting

Similar to ALPIX

Picture of Affluent Medical SAS logo

Affluent Medical SAS

fr flag iconEuronext - Paris

Picture of Alpha MOS SA logo

Alpha MOS SA

fr flag iconEuronext - Paris

Picture of Amplitude Surgical SA logo

Amplitude Surgical SA

fr flag iconEuronext - Paris

Picture of Biomerieux SA logo

Biomerieux SA

fr flag iconEuronext - Paris

Picture of Biosynex SA logo

Biosynex SA

fr flag iconEuronext - Paris

FAQ